Provided are a composition for stabilizing botulinum neurotoxin, a botulinum neurotoxin formulation including the same, and a polypeptide for use therein.
The present invention provides an antibody capable of effectively preventing or treating immune diseases associated with decreased autoantigen functions by competitively inhibiting autoantibodies without side effects, and a pharmaceutical composition comprising same for treating immune diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present disclosure is to provide a recombinant botulinum toxin type A light chain, a recombinant botulinum toxin, and a composition, use, and method related thereto, which exhibit improved efficacy and half-life to be easier to use for patients and enable treatment that is customized to indications.
The purpose of the present invention is to provide a recombinant botulinum toxin type A light chain in which efficacy and half-life are increased to increase patient convenience and allow for customized treatment for indications, a recombinant botulinum toxin, and a composition, use, and method related thereto.
Provided are heterodimeric Fc fusion proteins that are not only fast, simple, and efficient to purify, but also exhibit desirable therapeutic properties, such as increased FcRn binding capacity or increased FcγR binding capacity, and compositions, uses, methods related thereto.
The present disclosure relates to a hyaluronic acid cross-linked product and a filler composition including the same, and more specifically, to a hyaluronic acid cross-linked product with high cohesion and adhesion and reduced swelling, and a filler composition including the same.
IN-SILICO-DESIGNED BOTULINUM TOXIN MIMETIC PEPTIDE FOR INHIBITING RELEASE OF NEUROTRANSMITTERS INCLUDING ACETYLCHOLINE, AND USE THEREOF IN WRINKLE REDUCTION
The present invention relates to a peptide for inhibiting the release of neurotransmitters from cells, and provides a composition and a kit for skin whitening or wrinkle reduction, containing the peptide as an active ingredient, and a method for skin whitening or wrinkle reduction, wherein the peptide has cell permeability even if not fused with a protein transduction domain such as that of a cell-penetrating peptide, and thus effectively whitens skin or reduces wrinkles.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
Provided are: a botulinum toxin formulation comprising a botulinum toxin in an amount corresponding to a desired titer; a preparation method therefor; a cosmetic or therapeutic method using same; and a method for reducing the immunogenicity of a botulinum toxin formulation. Therefore, the formulation according to the present invention has low immunogenicity, and can exhibit low resistance expression when administered to a subject.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Provided are an anti-HVEM monoclonal antibody that binds to human HVEM with high affinity, and inhibits the binding of HVEM to BTLA but promotes the binding of HVEM to LIGHT, and thus can be used alone or in combination with other therapeutic agents to treat solid tumor or hematologic malignancy, and a composition and a method which are related to the antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a composition for stabilizing botulinum neurotoxin, a botulinum neurotoxin formulation containing same, and a polypeptide for use therein.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations for the treatment of cerebral palsy, headaches, migraines, ophthalmological disorders, hyperhidrosis, acne; muscle relaxants; therapeutic drugs and agents for the treatment of orthopaedic disorders, namely, hip dislocation, spinal column deformation, curvature of the spine, namely, scoliosis, lordosis, kyphosis; pharmaceutical preparations for treating the peripheral nervous system; bacterial poisons; pharmacological preparations for skin care; pharmaceutical agents for treating the epidermis; injectable dermal filler; pharmaceutical preparations for treating the central nervous system; pharmaceutical preparations for the treatment of muscle fatigue; vaccines
Provided are: a compound of chemical formula 1, having inhibitory activity against protein kinase, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and use thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Analgesics; Appetite suppressants for medical purposes; Pharmaceutical preparations acting on the central nervous system; Vaccines; Muscle relaxants; Injectable dermal filler for medical purpose; Pharmaceutical agents for epidermis; Pharmaceutical preparations for skin care; Antibiotic preparations; Bacterial poisons; Pharmaceutical agents affecting peripheral nervous system, namely, central nervous system stimulants, nasal and oral spray preparations for use as central nervous system stimulants, pharmaceutical preparations acting on the central nervous system; Dermatological pharmaceutical products; Pharmaceutical preparations for treating skin disorders; Analgesic and muscle relaxant pharmaceutical preparations; Medicated lotions for skin, hair, sunburn, face, body; Pharmaceutical ointments, namely, antibiotic ointments, anti-inflammatory ointments, anti-itch ointment, hemorrhoidal ointments; Hemorrhoid treatment preparations
20.
POLYPEPTIDE HAVING HAIR LOSS TREATING OR HAIR GROWTH PROMOTING ACTIVITY AND USE THEREOF
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Chemico-pharmaceutical preparations for treating glabellar lines, forehead wrinkles, lateral canthal line, prostate disorder, excessive eye blinking, and pelvic pain; muscle relaxants; anaesthetics; pharmaceutical agents affecting peripheral nervous system; bacterial poisons; pharmacological preparations for skin care, namely, pharmaceutical preparations for skin care; pharmaceutical preparations acting on the central nervous system; biological preparations for medical purposes being bacterial and bacteriological preparations; implantable medicines being medicinal infusions, injectable gels, injectable pharmaceuticals for use in the treatment of neurological disorders and muscle dystonia; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, prostate disorder, excessive eye blinking, and pelvic pain
23.
BOTULINUM TOXIN PRE-FILLED INJECTABLE FORMULATION THAT FACILITATES DISCHARGE RATE CONTROL AND IS STABLE
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle
The present disclosure relates to a Botulinum neurotoxin composition which has the effect of reducing spread and has an effect for an extended period of time.
Provided are a microorganism selected from the group consisting of Lactobacillus salivarius LMT15-14 (Accession No. KCTC14142BP) and Lactobacillus plantarum LMT19-1 (Accession No. KCTC14141BP) or a combination thereof or a culture or extract thereof, and a use thereof.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
The purpose of the present invention is to provide a recombinant botulinum toxin type A light chain in which efficacy and half-life are increased to increase patient convenience and allow for customized treatment for indications, a recombinant botulinum toxin, and a composition, use, and method related thereto.
The present invention is to provide a recombinant botulinum toxin type A light chain, a recombinant botulinum toxin, and a composition, use, and method related thereto, which exhibit improved efficacy and half-life to be easier to use for patients and enable treatment that is customized to indications.
The present invention relates to a hyaluronic acid cross-linked product and a filler composition comprising same and, more particularly, to a hyaluronic acid cross-linked product having reduced swelling while having high cohesive and adhesive strength, and a filler composition comprising same.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Implantable medicines for treating neurological disorders and muscle dystonia; implantable antiaging medicines, namely, botulinum toxin for medical use for treatment of facial wrinkles; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, excessive eye blinking, neuropathy pain and pelvic pain
Provided are an anti-HVEM monoclonal antibody, and a composition and method associated with same, wherein the antibody can bind to human HVEM with high affinity, and inhibits HVEM binding to BTLA and promotes HVEM binding to LIGHT, and thus, when used alone or in combination with other therapeutic agents, can be used to treat solid cancer or blood cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical agents affecting sensory organs; muscle relaxants; preparations for the treatment of muscle fatigue;pharmaceutical agents affecting peripheral nervous system; vaccines; pharmaceuticals containing botulinum toxin for medical use for use in treatment of excessive sweating, excessive eye blinking, neuropathy pain, facial wrinkles, glabellar lines, forehead wrinkles, lateral canthal line, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, neuropathy pain and pelvic pain; bacteria poisons;pharmacological preparations for skin care; chemico-pharmaceutical preparations for skin care, skin wounds, prevention of migraines; pharmaceutical agents for epidermis; biological preparations for medical or veterinary purposes being bacterial and bacteriological preparations; medicated lotions for skin, sunburn, face, body; pharmaceutical syringes prefilled with medical botulinum toxin as the main ingredient; medical infusions for treating migraine headaches, excessive sweating, urinary incontinence; injectable dermal fillers; implantable medicines being medicinal infusions, injectable gels, injectable pharmaceuticals for use in the treatment of anaphylactic reactions, migraine headaches, urinary incontinence, neurological disorders and muscle dystonia; pharmaceutical preparations acting on the central nervous system; pain relief medication; dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders
Provided are: a compound of chemical formula 1, having inhibitory activity against protein kinase, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof; and a use thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, namely, hyaluronate acid and modified hyaluronate acid for use as a soft tissue filler for treatment of damaged tissue; specialized medical capsules, namely, self-contained ampules sold filled with pharmaceuticals for use in dispensing the same in the nature of prepackaged hyaluronic acid and derivatives thereof alone, and in combination with other polysaccharide for pharmaceutical purposes in particular starch, cellulose esters, and with and without lidocaine; dermal tissue filler kits comprising hyaluronic acid gel sold in pre-filled syringes for injecting under the skin for use in reducing and eliminating fine skin lines and wrinkles, filling scars, and contouring the lips and face; pharmaceutical preparations, namely, hyaluronic acid and modified hyaluronic acid, and its derivatives and salts, and biological skin tissue for implantation, all sold in pre-filled syringes for eliminating fine skin lines and wrinkles Dermatological implants for medical use consisting of artificial materials in the nature of visco-supplementation substances for filling skin wrinkles and increasing skin volume
Provided are: a compound of chemical formula 1, having protein kinase inhibitory activity; a stereoisomer thereof or a pharmaceutically acceptable salt thereof; and a use thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
39.
ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME
Disclosed are a heterodimeric Fc fusion protein, and a composition, a use, and a method related to same, wherein the heterodimeric Fc fusion protein is not only simple, convenient, and efficient to formulate, but also shows preferable characteristics as a treatment drug, such as increased FcRn binding capability and increased FcγR binding capability.
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, for example, as described for methods 1, 1A, 1B, 2, 3, 3A, and 4. The method can start with a plant derived steroid as a starting material, such as dehydroepiandrosterone (DHEA) or Acetyl-dehydroepiandrosterone (Ac-DHEA). Also provided are pharmaceutical or cosmetic compositions and uses thereof, which comprise one or more of cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, which is of high purity, for example, free of animal derived impurities.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
44.
HIGH-CONCENTRATION ANTI-VEGF ANTIBODY PREPARATION AND ANTI-VEGF ANTIBODIES FOR USE THEREIN
Disclosed are a stable aqueous pharmaceutical composition containing a high-concentration of anti-VEGF antibodies, and anti-VEGF antibodies suitable for use in the composition.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
Provided are a microorganism selected from the group consisting of Lactobacillus salivarius LMT15-14 (accession number: KCTC14142BP) and Lactobacillus plantarum LMT19-1 (accession number: KCTC14141BP), or a combination thereof, or a culture or an extract thereof, and uses of same.
Provided are extracellular vesicles (EVs) derived from a recombinant microorganism including one or more polynucleotides encoding one or more target proteins, extracellular vesicles isolated from the microorganism, and a use of the extracellular vesicles.
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
50.
EXTRACELLULAR VESICLES DERIVED FROM RECOMBINANT CELLS INCLUDING POLYNUCLEOTIDE ENCODING IL-1 INHIBITOR AS TARGET PROTEIN AND USE THEREOF
The present invention relates to extracellular vesicles isolated from recombinant cells including a polynucleotide encoding an IL-1 inhibitor as a target protein, and use thereof.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
51.
Methods and compositions of bile acids and salts for reduction of fat
The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/00 - Medicinal preparations characterised by special physical form
A61Q 19/06 - Preparations for care of the skin for countering cellulitis
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, for example, as described for methods 1, 1A, 1B, 2, 3, 3A, and 4. The method can start with a plant derived steroid as a starting material, such as dehydroepiandrosterone (DHEA) or Acetyl-dehydroepiandrosterone (Ac-DHEA). Also provided are pharmaceutical or cosmetic compositions and uses thereof, which comprise one or more of cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, which is of high purity, for example, free of animal derived impurities.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
53.
Microorganism having ability to degrade ethanol and acetaldehyde, and composition and kit each including the same
Provided are a VIP gene-expressing microorganism, a composition comprising the microorganism for prevention or treatment of a disease causative of gastrointestinal damage, a kit, and a method for prevention or treatment of a disease causative of gastrointestinal damage.
The present invention provides: a primer specific to a non-toxic non-hemagglutinin (NTNH) protein gene sequence; a kit for detecting a subject producing a botulinum neurotoxin comprising the primer; a method for amplifying a gene that encodes a non-toxic non-hemagglutinin protein in a sample; and a method for detecting bacteria that produce botulinum neurotoxin in a sample.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Provided are: a pluripotent stem cell culture medium which contains a GSK-3β inhibitor, a DYRK inhibitor, and an NFAT inhibitor; and a culture method using same.
Provided is a method of isolating a botulinum toxin type A macro complex from a botulinum toxin-containing solution, the method including performing anion exchange chromatography and cation exchange chromatography.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
B01J 47/028 - Column or bed processes using columns or beds of different ion exchange materials in series with alternately arranged cationic and anionic exchangers
58.
EXTRACELLULAR VESICLES DERIVED FROM RECOMBINANT MICROORGANISM INCLUDING POLYNUCLEOTIDE ENCODING TARGET PROTEIN AND USE THEREOF
Provided are extracellular vesicles (EVs) derived from a recombinant microorganism including one or more polynucleotides encoding one or more target proteins, extracellular vesicles isolated from the microorganism, and a use of the extracellular vesicles.
Provided are a promoter polynucleotide, a signal polypeptide and a polynucleotide encoding the signal polypeptide, and use thereof. A vector and a host cell each including the promoter polynucleotide and the polynucleotide encoding the signal polypeptide may efficiently express and/or extracellularly secrete a foreign protein.
Recombinant polynucleotide coding for polypeptide comprising reporter moiety, substrate moiety and destabilizing moiety, host cell comprising same and use of same
Provided are a recombinant polynucleotide encoding a polypeptide including a reporter moiety, a substrate moiety, and a destabilization moiety, a host cell including the same, and use thereof to measure the level of a protease by using the recombinant polynucleotide.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, for example, as described for methods 1, 1A, 1B, 2, 3, 3A, and 4. The method can start with a plant derived steroid as a starting material, such as dehydroepiandrosterone (DHEA) or Acetyl-dehydroepiandrosterone (Ac-DHEA). Also provided are pharmaceutical or cosmetic compositions and uses thereof, which comprise one or more of cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, which is of high purity, for example, free of animal derived impurities.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
C07J 13/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, having a carbon-to-carbon double bond from or to position 17
C07J 75/00 - Processes for the preparation of steroids, in general
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
Provided is a method of isolating a botulinum toxin type A macro complex from a botulinum toxin-containing solution, the method including performing anion exchange chromatography and cation exchange chromatography.
C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
64.
RECOMBINANT POLYNUCLEOTIDE CODING FOR POLYPEPTIDE COMPRISING REPORTER MOIETY, SUBSTRATE MOIETY AND DESTABILIZING MOIETY, HOST CELL COMPRISING SAME AND USE OF SAME
Provided are recombinant polynucleotide coding for polypeptide comprising a reporter moiety, a substrate moiety and a destabilizing moiety, a host cell comprising same and a method for measuring a protease level by means of same.
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
The present invention relates to: an antibody against CD3γε or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector comprising the nucleic acid; cells transformed with the vector; a method for preparing the antibody or the antigen-binding fragment thereof; a composition for preventing or treating T cell-mediated diseases, comprising same; and a method for treating T cell-mediated diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an animal model expressing human CD3 and a use thereof, and more specifically, to: an animal model into which a gene encoding human CD3 has been introduced; a method for producing the animal model; and a method for screening a therapeutic agent for T cell-mediated diseases using the animal model.
The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61Q 19/06 - Preparations for care of the skin for countering cellulitis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations; muscle
relaxants; therapeutic drugs and agents; pharmaceutical
preparations for peripheral nervous system; bacterial
poisons; pharmacological preparations for skin care;
pharmaceutical agents for epidermis; injectable dermal
filler; pharmaceutical preparations for central nervous
system; dermatological pharmaceutical products;
pharmaceutical preparations for treating skin disorders;
biological preparations for medical or veterinary purposes;
preparations for the treatment of muscle fatigue; vaccines;
medicated lotions; ointments for pharmaceutical purposes.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; drugs for
medical purposes; pharmaceutical drugs; medical preparations
made of solutions of hyaluronic acid or modified hyaluronic
acid; medical hyaluronic acid or modified hyaluronic acid in
the form of pre-filled syringes; medical hyaluronic acid or
modified hyaluronic acid used for treatment or prevention of
arthritis or osteoarthritis in the form of injection to
inject into joints; preparations for treating arthritis;
preparations for treating osteoarthritis; improving
preparations for articular function (medical purposes). Medical filler syringes; syringes for injection of medical
substances; syringes for medical purposes and for
injections; injection device for pharmaceuticals; medical
apparatus and instruments other than for dental purposes;
joint prostheses; injection devices for pharmaceuticals,
used to inject hyaluronic acid for treatment or prevention
of arthritis or osteoarthritis.
70.
TEMPERATURE SENSITIVE ADHESION PREVENTION COMPOSITION AND USE THEREOF
Provided are a temperature sensitive adhesion prevention composition and a method for producing the same, the composition comprising a polyethylene oxide (PEO) containing copolymer, a carboxy polysaccharide, and a monovalent cation.
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
PHARMACEUTICAL COMPOSITION, FOR TREATING OSTEOARTHRITIS, COMPRISING CROSS-LINKED HYALURONIC ACID AS ACTIVE INGREDIENT AND OSTEOARTHRITIS TREATMENT METHOD USING SAME
The present invention relates to a composition for inhibiting cartilage damage and/or for preventing and treating arthritis, the composition comprising cross-linked hyaluronic acid and, more specifically, to cross-linked hyaluronic acid which has excellent cartilage protective effect in an animal model of chronic osteoarthritis or an animal model of acute osteoarthritis and thereby can be utilized for inhibiting cartilage damage and/or preventing and treating arthritis.
PHARMACEUTICAL COMPOSITION, FOR TREATING OSTEOARTHRITIS, COMPRISING BOTULINUM TOXIN AS ACTIVE INGREDIENT AND OSTEOARTHRITIS TREATMENT METHOD USING SAME
Provided are a composition, for inhibiting osteoarthritis, comprising a botulinum toxin as an active ingredient and an osteoarthritis treatment method using same.
The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer lasting effect in the patient compared to an animal-protein-containing botulinum toxin composition.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, namely hyaluronate acid or modified
hyaluronate acid for use as a soft tissue filler; medical
devices, namely, self-contained ampules for dispensing
prepackaged hyaluronic acid and derivatives thereof alone,
or in combination with other polysaccharide and with or
without lidocaine; dermal filler kits comprising of a
hyaluronic acid gel in a pre-filled syringe, injected under
the skin, used to reduce of eliminate fine lines and
wrinkles, fill scars and contour the lips and face;
pre-filled syringes containing pharmaceutical preparations
and prostheses, namely, hyaluronic acid or modified
hyaluronic acid or one of its derivatives or salts or a
substance having a skin tissue. Dermic implants, including visco-supplementation substances
for medical use, intended for wrinkle filling or volume
increasing.
The present invention provides a lyophilized preparation of botulinum toxin that does not contain an animal-derived protein-stabilizing agent. The lyophilized preparation of botulinum toxin according to the present invention may maintain botulinum toxin activity and achieve remarkably superior long-term stability even under high-temperature conditions which might occur during storage, transportation, or use of botulinum toxin.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Botulinum toxin for the treatment of muscle spasms;
pharmaceutical preparations for the treatment of frown
lines, glabellar lines and other facial wrinkles;
pharmaceutical preparations for use in cosmetic surgery;
pharmaceutical preparations for skin care; pharmaceutical
preparations for the treatment of pain, pharmaceutical
preparations for the treatment of hemi facial spasm and/or
blepharospasm; pharmaceutical preparations for the treatment
of dystonia; pharmaceutical preparations for the treatment
of torticollis; pharmaceutical preparations for the
treatment of cerebral palsy; pharmaceutical preparations for
the treatment of articular pathologies; pharmaceutical
preparations for the treatment of acne; pharmaceutical
preparations for the treatment of headache; pharmaceutical
preparations for the treatment of migraine; pharmaceutical
preparations for the treatment of hyperhydrosis;
pharmaceutical preparations for the treatment of myofascial
pain; pharmaceutical preparations for the treatment of
muscular disorders; pharmaceutical preparations for the
treatment of neurological disorders; pharmaceutical
preparations for the treatment of orthopedic disorders;
pharmaceutical preparations for the treatment of disorder
relating to age; pharmaceutical preparations for the
treatment of ophthalmological disorders.
78.
METHOD OF PRODUCING CLOSTRIDIUM BOTULINUM TOXIN USING MEDIA CONTAINING PLANT-DERIVED COMPONENTS AND FLEXIBLE CLOSED CONTAINER
Provided are a method of producing Clostridium botulinum toxin by using a media containing plant-derived components, and a method of producing Clostridium botulinum toxin by using a flexible closed container.
Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of theanimal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum- derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25 ~ 370C as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature. The liquid pharmaceutical composition can be readily prepared because it employs a detergent and an amino acid(s) without a lyophilization process.
